GlassScriptPhysician profile
Ricardo A Henriques
NPI 1043323231
$7,285.80
in general payments reported to CMS, 2019-2025
29 companies · $747 in 2025
The $747 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $510 · 2020: $376 · 2021: $735 · 2022: $1,373 · 2023: $1,998 · 2024: $1,547 · 2025: $747.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,292.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,291.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $881.52 | 2019-2025 | Enhertu, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $623.34 | 2021-2025 | Opdivo, Augtyro |
| Genentech USA, INC. | $563.53 | 2021-2023 | Lunsumio |
| Kite Pharma, INC. | $368.00 | 2022-2024 | Yescarta |
| Bayer Healthcare Pharmaceuticals INC. | $367.72 | 2022-2025 | |
| Genzyme Corporation | $359.72 | 2022-2024 | |
| Amgen INC. | $354.33 | 2023-2024 | Nplate, Kyprolis |
| Merck Sharp & Dohme LLC | $316.82 | 2019-2023 | Lynparza, Keytruda |
| Glaxosmithkline, LLC. | $249.44 | 2022-2025 | Ojjaara |
| Astellas Pharma US INC | $248.92 | 2023-2024 | Xtandi |
| Emd Serono, INC. | $245.11 | 2022-2024 | |
| Janssen Biotech, INC. | $244.91 | 2021-2025 | Carvykti, Rybrevant |
| Jazz Pharmaceuticals INC. | $224.81 | 2022-2023 | |
| G1 Therapeutics, INC. | $223.25 | 2021-2023 | Cosela |
| Regeneron Healthcare Solutions, INC. | $213.40 | 2023-2024 | Libtayo |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $175.12 | 2019-2020 | |
| Daiichi Sankyo INC. | $169.44 | 2020-2022 | |
| Coherus Oncology, INC. | $144.84 | 2024 | |
| Incyte Corporation | $127.40 | 2023 | Pemazyre |
| Ipsen Biopharmaceuticals, INC | $127.30 | 2023 | Tazverik |
| Verastem, INC. | $125.01 | 2019 | |
| Gilead Sciences, INC. | $124.46 | 2024 | Trodelvy |
| Seagen INC. | $123.83 | 2023 | Adcetris |
| Syndax Pharmaceuticals, INC. | $123.69 | 2025 | |
| Exelixis INC. | $123.19 | 2022 | |
| Mirati Therapeutics, INC. | $120.65 | 2023 | Krazati |
| Advanced Accelerator Applications | $114.27 | 2020 | |
| Abbvie INC. | $102.72 | 2022 | |
| Pfizer INC. | $99.06 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ricardo Henriques listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.